EPO and anemia (phenotype): This has been impressively demonstrated for a hyperglycosylated EPO variant (darbepoetin alfa) that is glycosylated at two additionally introduced N‐glycosylation sites and has been approved for treatment of anaemia (Elliott et al., 2003).